NDAORALTABLET
Approved
Mar 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
5/8 — Partial
DETROL (tolterodine tartrate) by Viatris (2) is clinical pharmacology tolterodine is a competitive muscarinic receptor antagonist. First approved in 1998.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DETROL (tolterodine tartrate) is an oral small-molecule muscarinic receptor antagonist approved in 1998 for overactive bladder. It works by blocking cholinergic signaling in the bladder to reduce involuntary contractions and urinary urgency. The drug is metabolized to a pharmacologically active 5-hydroxymethyl metabolite that contributes significantly to therapeutic effect.
$0.099BPart D
LOE ApproachingProduct is entering loss-of-exclusivity phase with minimal growth runway, signaling team reductions and transition to generic support models.
Mechanism of Action
CLINICAL PHARMACOLOGY Tolterodine is a competitive muscarinic receptor antagonist. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of the 5-hydroxymethyl…
Worked on DETROL at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.